We develop transformative therapies for patients with serious unmet medical needs, from diabetic foot disease to rare genetic disease.
Triovance was founded to develop innovative treatments for diabetes, inspired by the founders' personal loss of their fathers to the disease. The company began in Mexico, focusing on gene and cell therapies, and in 2019 secured funding from Jaime Cervantes, president of the Vitalmex Group, to tackle diabetic foot ulcers. After five years of research, Triovance developed a breakthrough skin substitute designed to be safe, affordable, and accessible for low-income patients.
In 2023, Triovance received FDA feedback during its first pre-IND meeting, leading to the formation of Triovance Holding LLC in San Diego, CA.
With an experienced manufacturing team and support from Azzur Cleanrooms on Demand, the company scaled production under Good Manufacturing Practices (GMP). Triovance is driven by an experienced team, expert advisors and key partners, who are all committed to expanding operations and delivering life-changing solutions for patients in need.
Our mission is to develop transformative therapies for patients with rare and chronic-degenerative diseases — conditions where few or no treatment options exist — using innovative science based on tissue engineering, gene therapy, and cell therapy. Today that includes TRV-01 for diabetic foot ulcers and PTT-621 for ROSAH syndrome, a rare genetic disease.
Triovance's expansion into rare disease reflects our commitment to reaching patients with the greatest unmet need. Through PTT-621, an investigational ALPK1 inhibitor for ROSAH syndrome, we're extending our science beyond wound care into a disease area where patients and families have had few options. As we advance this program, we plan to seek external collaborations with specialized expertise in ROSAH syndrome.
Meet the team behind Triovance
Blanca Segura, PhD
Blanca is a 20+ year cell and gene therapy expert and seasoned inventor of innovative research methods and medical devices, including co-development of an epigenetic drug and co-invention of two medical devices for diabetes. As founder and CEO of Triovance, she leads the company in advancing a portfolio of products that address type 2 diabetes and its complications. Previously, she served as CSO at Global BioTherapeutics and PI and researcher at the National Cancer Institute, Mexico.
Ian Wisenberg
Ian Wisenberg is an international business executive with more than 35 years of experience spanning corporate development, finance, and strategic partnerships. He has played a significant role in helping life sciences and healthcare companies’ access and expand across global markets in the United States, Europe, and Asia. He currently serves as Chairman and CEO of Triovance, Managing Director of BioGlobal Consulting Group, and Director of Clever Culture Systems. In these roles, he focuses on strategic growth, financing, cross-border business development, and the formation of high-value partnerships. Previously, Ian served as CEO, Co-founder, and Executive Chairman of BioCina, and as CFO of BioDuro. Over the course of his career, he has built a strong reputation for aligning capital, commercial strategy, and international relationships to support company growth and value creation.
Clinical & Scientific Advisors
%203.33.33%E2%80%AFp.m..png)
Professor of Surgery at the USC. Dr. Armstrong holds a M of Sc in Tissue Repair and Wound Healing from the U of Wales and a PhD from the U of Manchester. Has produced more than 595 peer-reviewed. Was selected as one of the first six International Wound Care Ambassadors. Founder and co-chair of the International Diabetic Foot Conference. Founding President of the American Limb Preservation Society (ALPS)
30+ years commercial experience in life sciences, focusing on cell & gene therapy. Co-founder of numerous companies, Senior VP of R&D at New York Stem Cell Fdn, Co-author of 30+ published papers, inventor on 50+ patents worldwide, and has filed over 15 INDs at the FDA.
Dr. Dennis Kim, President and CEO of Xeno Biosciences, is an endocrinologist and specializes in metabolic diseases. He has held senior roles at CymaBay, Orexigen, and Amylin Pharmaceuticals, where he led the development of Byetta® for type 2 diabetes.
Dan Maneval is a scientific leader with extensive biotech and biopharma experience, contributing to all stages of drug development, including Herceptin®, Adstiladrin®, HYQVIA™, and HYLECTA™.
He is the recipient of the 21st Annual John Boswick Award for lifelong achievement in the field of wound care. Program Director, Vascular and Wound Care Center New Jersey Medical School. He is also a Voluntary Associate Professor, Phillip Frost Department of Dermatology and Cutaneous Surgery
